HERTFORDSHIRE, England and
PITTSBURGH, Feb. 22, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced the appointment of Anthony (Tony) Mauro to chief commercial
officer.
In his new role, which reports to Mylan President Rajiv Malik, Mauro will now be responsible for
overseeing global sales excellence and operations of all commercial
markets around the world. Until his successor is appointed, Mauro
will continue his current role as president of North America.
Mauro has been with Mylan for more than 20 years and has
successfully led its largest commercial business – the North
American region – for the last four of them. He has served the
company in several capacities of increasing responsibility,
including president of Mylan Pharmaceuticals Inc., the company's
flagship generics division in the U.S.; chief operating officer of
Mylan Pharmaceuticals ULC in Canada; vice president of North America
Strategic Development; and vice president of North America Sales.
Mauro also served as chairman of the board of directors for the
U.S. Generic Pharmaceutical Association (GPhA) for two consecutive
terms in 2012 and 2013, and prior to that served two consecutive
terms as vice chairman of the board for GPhA.
Mylan CEO Heather Bresch
commented: "Tony has been instrumental in Mylan's success to date,
particularly in his strong leadership of our North American
commercial business. During his tenure, Tony has demonstrated his
ability to relentlessly drive innovation, provide our customers
with exceptional and reliable service, and has maximized
opportunities while overcoming challenges and consistently
delivered strong financial performance. In Tony's new leadership
role, Mylan will be better positioned for Tony to continue to drive
sales excellence throughout all of Mylan's global commercial
markets."
Mylan President Rajiv Malik
added: "Tony has demonstrated a proven track record of driving
success in our North America
commercial operations and enhancing our relationships with
customers, particularly as they continue to expand globally. As a
result, Tony has certainly earned the opportunity to continue his
success with Mylan and now by driving global sales excellence
throughout our global commercial operations. I look forward to his
continued strong partnership and strategic input as we continue to
grow and strengthen our business in existing markets and expand our
commercial footprint in new regions."
Mauro said: "I have had the privilege of being part of Mylan for
more than 20 years and contributing to the company's evolution from
a leading generics pharmaceutical company in the U.S. to a leading
global pharmaceutical company. Mylan's future has never been
brighter, and I am proud to have been recognized and ready to step
up to be a part of Mylan's senior organizational leadership team as
we continue our exciting growth trajectory, while delivering on our
mission to set new standards in healthcare."
This press release includes statements that constitute
"forward-looking statements," including with regard to Mylan being
better positioned under Mauro's leadership to identify commercial
opportunities and best practices across the various regions to
bring even greater value to its customers around the world and to
continue its efforts to provide 7 billion people access to high
quality medicine; that Mylan's future has never been brighter; and
about Mylan's exciting growth trajectory and its mission to set new
standards in healthcare. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: the effect of any changes in our customer
and supplier relationships and customer purchasing patterns; other
changes in third-party relationships; the impact of competition;
changes in the economic and financial conditions of the businesses
of Mylan; the scope, timing, and outcome of any ongoing legal
proceedings and the impact of any such proceedings on our business;
any regulatory, legal, or other impediments to our ability to bring
our products to market; actions and decisions of healthcare and
pharmaceutical regulators, and changes in healthcare and
pharmaceutical laws and regulations, in the United States and abroad; our ability to
protect our intellectual property and preserve intellectual
property rights; other uncertainties and matters beyond the control
of management; and the other risks detailed in the company's
filings with the Securities and Exchange Commission. The company
undertakes no obligation to update these statements for revisions
or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which nearly 50% of people
being treated for HIV/AIDS in the developing world depend. We
market our products in approximately 165 countries and territories.
Our global R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our nearly
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-appoints-anthony-mauro-chief-commercial-officer-300223497.html
SOURCE Mylan N.V.